Northpointe Capital LLC decreased its stake in Halyard Health, Inc. (NYSE:HYH) by 6.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 208,426 shares of the medical instruments supplier’s stock after selling 15,464 shares during the period. Northpointe Capital LLC owned approximately 0.45% of Halyard Health worth $8,187,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. CENTRAL TRUST Co raised its stake in Halyard Health by 1.0% in the first quarter. CENTRAL TRUST Co now owns 2,643 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 25 shares during the period. Meadow Creek Investment Management LLC raised its stake in Halyard Health by 1.1% in the first quarter. Meadow Creek Investment Management LLC now owns 2,660 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 28 shares during the period. Glen Harbor Capital Management LLC raised its stake in Halyard Health by 1.1% in the first quarter. Glen Harbor Capital Management LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $123,000 after buying an additional 34 shares during the period. LS Investment Advisors LLC raised its stake in Halyard Health by 16.1% in the second quarter. LS Investment Advisors LLC now owns 4,017 shares of the medical instruments supplier’s stock valued at $158,000 after buying an additional 556 shares during the period. Finally, Victory Capital Management Inc. acquired a new stake in Halyard Health during the first quarter valued at $153,000. Hedge funds and other institutional investors own 90.32% of the company’s stock.

Halyard Health, Inc. (NYSE:HYH) opened at 41.90 on Tuesday. Halyard Health, Inc. has a 12-month low of $31.59 and a 12-month high of $43.78. The stock has a 50 day moving average of $40.23 and a 200 day moving average of $38.87. The company has a market capitalization of $1.96 billion, a PE ratio of 40.29 and a beta of 1.78.

Halyard Health (NYSE:HYH) last announced its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.14. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. The company had revenue of $399.20 million during the quarter, compared to the consensus estimate of $399.16 million. During the same period in the previous year, the firm posted $0.45 earnings per share. The company’s revenue was down .2% on a year-over-year basis. On average, equities research analysts predict that Halyard Health, Inc. will post $1.98 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/08/15/northpointe-capital-llc-decreases-stake-in-halyard-health-inc-hyh.html.

Several research firms recently weighed in on HYH. Stephens upgraded shares of Halyard Health from an “equal weight” rating to an “overweight” rating in a research note on Thursday, August 3rd. Deutsche Bank AG upped their target price on shares of Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. BidaskClub cut shares of Halyard Health from a “buy” rating to a “hold” rating in a research report on Saturday, July 8th. Zacks Investment Research cut shares of Halyard Health from a “buy” rating to a “hold” rating in a research report on Thursday, May 4th. Finally, TheStreet cut shares of Halyard Health from a “b-” rating to a “c” rating in a research report on Wednesday, May 3rd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $42.25.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Institutional Ownership by Quarter for Halyard Health (NYSE:HYH)

Receive News & Stock Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related stocks with our FREE daily email newsletter.